Table 2 Clinical trials with compounds of IDH inhibitors in patients with hematologic malignancies
From: Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia
Compound | Target | Phase | Registration number | Reference |
|---|---|---|---|---|
IDH305 | IDH1 | 1 | NCT02381886 | 83 |
AG120 | IDH1 | 1 | NCT02074839 | 84 |
AG120 | IDH1 | 1 | NCT02073994 | 82 |
AG221 | IDH2 | 1/2 | NCT01915498 | 86 |
AG221 | IDH2 | 1/2 | NCT02273739 | NA |
AG221 | IDH2 | 3 | NCT02577406 | NA |
AG-120/AG-221 | IDH1/IDH2 | 1 | NCT02632708 | NA |
AG-120/AG-221 | IDH1/IDH2 | 1b/2 | NCT02677922 | NA |